This article is more than 5 years old. Information may no longer be current.
Gilead focuses on combination therapy to treat NASH fibrosis
Click Here to Manage Email Alerts
PARIS — In this exclusive interview from the International Liver Congress 2018, Mani Subramanian, PhD, discusses innovative approaches to treating advanced fibrosis in patients with nonalcoholic steatohepatitis.
“What is very exciting is the number of programs that are looking at single-agents targeting different aspects of NASH,” Subramanian, senior vice president of liver disease therapeutics at Gilead, told Healio Gastroenterology and Liver Disease. “The results of these studies will be available in the first half of 2019, but the primary endpoint is based on a liver biopsy to show reduction of liver fibrosis with no worsening of the components of NASH.”
Subramanian provided details about the STELLAR 3 and STELLAR 4 studies being conducted by Gilead for the treatment of fibrosis stage 3 and stage 4, respectively. The studies were designed to test combination therapy to improve outcomes. According to Subramanian, the results should be available in the first half of 2019.
“So the way we view the development of therapies for NASH, especially for these patients who have advanced fibrosis, is start with monotherapies ... but then innovate, to look at combinations and select the optimal combination for these patients to further enhance therapeutic benefit,” Subramanian said.
Disclosure: Subramanian is an employee of Gilead.